Elicera Therapeutics AB

Chart & Performance

D1W1MN

P/E

—

P/S

44.19

EPS

—

Div Yield, %

—

Shrs. gr., 5y

21.28%

Rev. gr., 5y

Revenues

-36.53%

Net income

-16m

L-1.76%

CFO

-23m

L+57.23%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.

URL

https://www.elicera.com/

IPO date

Jun 11, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title SEK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title SEK in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT